Menu Search
Equities

Telix Pharmaceuticals Limited

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TLX:ASX

Telix Pharmaceuticals Limited

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)15.34
  • Today's Change-0.44 / -2.79%
  • Shares traded1.11m
  • 1 Year change+6.82%
  • Beta0.9239
Data delayed at least 20 minutes, as of Oct 14 2026 06:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Telix Pharmaceuticals Limited had net income fall from a gain of 33.69m to a loss of 7.13m despite a 55.61% increase in revenues from 516.55m to 803.79m. An increase in the cost of goods sold as a percentage of sales from 38.15% to 52.49% was a component in the falling net income despite rising revenues.
Gross margin47.57%
Net profit margin3.76%
Operating margin7.71%
Return on assets2.63%
Return on equity7.37%
Return on investment3.33%
More ▼

Cash flow in USDView more

In 2025, cash reserves at Telix Pharmaceuticals Limited fell by 298.13m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 17.29m for operations while cash used for investing totalled 285.92m.
Cash flow per share0.2392
Price/Cash flow per share66.24
Book value per share2.06
Tangible book value per share-0.41
More ▼

Balance sheet in USDView more

Telix Pharmaceuticals Limited has a Debt to Total Capital ratio of 54.32%, a lower figure than the previous year's 94.13%.
Current ratio2.01
Quick ratio1.85
Total debt/total equity1.19
Total debt/total capital0.5432
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.